The best performing sector in the stock market for the past year has been the unsung financial sector. Its 24% return through ...

According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 13.11%, which ...

Good relative valuations and an encouraging price action led me to view healthcare positively while keeping in mind the ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by ...

Vor Biopharma, (NYSE:VOR)  listed on the NYSE Composite, is part of the biotechnology space and has recently garnered ...

VEEV's niche focus and strong margins give it an edge over CRM despite its higher valuation and smaller scale.

Minimize investment losses with broad diversification. Find out how our Income Method protects your financial well-being ...

Markets around the world, including the US and China, all took a big drop during the uncertainty surrounding President ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

Lyra Therapeutics reported 0% EPS growth last quarter, while sales growth came in at -66%. Lyra Therapeutics holds the No. 250 rank among its peers in the Medical-Biomed/Biotech i ...

Stocks in this industry have collectively risen 3.9% so far this year against the Zacks Medical Sector’s decline of 1.5%. The Zacks S&P 500 composite has risen 1.7%. YTD Price Performance ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...